Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

Kenneth B. Gordon, Andrew Blauvelt, Kim Papp et al. · New England Journal of Medicine · 2016 · 838 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

C.E.M. Griffiths, Kristian Reich, Mark Lebwohl et al. · The Lancet · 2015 · 831 citations

Medicine, Immunology, Pharmacotherapy +10

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)

Andrew Blauvelt, Melinda Gooderham, Lars Iversen et al. · Journal of the American Academy of Dermatology · 2017 · 113 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Methods for Imputing Missing Efficacy Data in Clinical Trials of Biologic Psoriasis Therapies: Implications for Interpretations of Trial Results.

Richard G. Langley, Kristian Reich, C. Papavassilis et al. · PubMed · 2017 · 22 citations

Medicine, Clinical Sciences, Dermatology +17